GSK PLC Sponsored ADR (GSK)
(Delayed Data from NYSE)
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$43.55 USD
+0.54 (1.26%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $43.55 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth A Momentum A VGM
Zacks News
GSK's Q2 Earnings Beat, Sales Miss, Raises 2022 Guidance
by Zacks Equity Research
GSK's (GSK) revenues benefit from the strong growth in sales across all segments. The company raises its financial guidance for its Vaccines segment on the back of strong shingles vaccine sales.
Drug, Biotech Stocks' Q2 Earnings on Jul 27: BMY, GSK & More
by Zacks Equity Research
Let's look what is in store for the four drug, biotech companies slated to release quarterly results tomorrow- BMY, GSK, ALKS, TEVA
GSK Gears Up to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
The newer respiratory and HIV drugs of GSK are likely to have driven second-quarter sales. The performance of Xevudy, GSK's monoclonal antibody for COVID-19, remains to be seen when the company reports.
The Zacks Analyst Blog Highlights J&J, Novartis, GSK, Merck and AbbVie
by Zacks Equity Research
J&J, Novartis, GSK, Merck and AbbVie are included in this Analyst Blog.
GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $42.29 in the latest trading session, marking a +0.09% move from the prior day.
Pharma Stock Roundup: JNJ, NVS Q2 Earnings, GSK Consumer Unit Spin-Off
by Kinjel Shah
J&J (JNJ) and Novartis (NVS) report Q2 earnings. GSK completes separation of its Consumer Healthcare (CHC) segment.
Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fiscal fourth-quarter results.
GSK Completes Demerger of Consumer Healthcare Business
by Zacks Equity Research
Post demerger, GSK is set to focus on its Pharmaceuticals and Vaccines businesses. The consumer healthcare business, Haleon, will start regular-way trading on the NYSE from Jul 22.
The Zacks Analyst Blog Highlights Apple, UnitedHealth Group, Equinor, GSK and Eaton
by Zacks Equity Research
Apple, UnitedHealth Group, Equinor, GSK and Eaton have been included in this Analyst Blog.
Top Analyst Reports for Apple, UnitedHealth, Equinor & Others
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Apple Inc. (AAPL), UnitedHealth Group Incorporated (UNH), and Equinor ASA (EQNR).
GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $40.22 in the latest trading session, marking a -1.71% move from the prior day.
Theravance Biopharma (TBPH) to Sell Trelegy Royalty Interests
by Zacks Equity Research
Theravance Biopharma (TBPH) agrees to sell its Trelegy royalty interests to Royalty Pharma. The latter also acquires Innoviva???s Trelegy royalty shares.
GlaxoSmithKline (GSK) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $40.92 in the latest trading session, marking a -1.25% move from the prior day.
GlaxoSmithKline (GSK) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $43.32, marking a +0.49% move from the previous day.
GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $43.30, marking a -1.03% move from the previous day.
GlaxoSmithKline (GSK) Stock Moves -0.8%: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed the most recent trading day at $43.35, moving -0.8% from the previous trading session.
Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA
by Zacks Equity Research
Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.
Gilead (GILD) HIV Candidate Gets Positive CHMP Recommendation
by Zacks Equity Research
Gileads (GILD) lenacapavir gets a positive CHMP opinion for the treatment of HIV-1 infection.
Gilead (GILD) Announces Positive Data on Hepcludex for HDV
by Zacks Equity Research
Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.
GlaxoSmithKline (GSK) Gains As Market Dips: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $41.97 in the latest trading session, marking a +0.48% move from the prior day.
Top Analyst Reports for Alphabet, Bank of America & Charles Schwab
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Alphabet Inc. (GOOGL), Bank of America Corporation (BAC), and The Charles Schwab Corporation (SCHW).
GlaxoSmithKline (GSK) Stock Moves -0.74%: What You Should Know
by Zacks Equity Research
In the latest trading session, GlaxoSmithKline (GSK) closed at $41.64, marking a -0.74% move from the previous day.
GlaxoSmithKline (GSK) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
GlaxoSmithKline (GSK) closed at $41.95 in the latest trading session, marking a +1.72% move from the prior day.
Sanofi (SNY), GSK COVID Booster Jab Effective Against Omicron
by Zacks Equity Research
Data from clinical studies show that Sanofi (SNY) and Glaxo's (GSK) next-generation COVID-19 booster candidate elicits a stronger immune response in adults who received an mRNA vaccine as a primary regimen.
GSK's RSV Vaccine Candidate Offers Robust Protection in Elderly
by Zacks Equity Research
GSK's RSV vaccine candidate for adults aged 60 years or above achieves statistically significant and clinically meaningful efficacy in a phase III study. Regulatory submissions are likely in the second half of 2022.